NAD reviews OS-CAL
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline has agreed to modify disclaimer language for OS-CAL following a review by the National Advertising Division of the Council for Better Business Bureaus, according to a June 8 release from the watchdog group. NAD determined the claim, "Only OS-CAL is proven to help reduce risk of hip fractures by 29%," was substantiated by the results of the Women's Health Initiative. However, NAD recommended the company drop the "among calcium supplements" disclaimer for the claim "to avoid any implication that the study compared competing calcium supplements," the release says. The review was part of NAD's ongoing monitoring program. The self-regulatory group notes its review of dietary supplement advertising has expanded because of a series of grants from supplement trade group the Council for Responsible Nutrition (1"The Tan Sheet" April 30, 2007, p. 13)...
You may also be interested in...
In First CRN-Funded Case, NAD Questions CH-Alpha Cartilage Health Claim
The National Advertising Division, in its first investigation supported by the Council for Responsible Nutrition, recommended Gelita Health Products discontinue or modify a health claim for its CH-Alpha product
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.